NCT02075840 · OUTCOME

Overall Survival (OS)

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants · Source last updated 2026-05-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: From randomization until death (up to 10.5 years)

What was measured

Overall survival (OS) was defined as the time from randomization to death from any cause.

Analysis population: ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.

Groups in this outcome

Alectinib

Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.

Crizotinib

Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Alectinib	152
Crizotinib	151

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Alectinib	81.1	Not reported	62.3	NA	Value is NA due to an insufficient number of participants with the event.
Crizotinib	54.2	Not reported	34.6	75.6	Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

ci Lower Limit
0.56
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
1.08
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY
p Value
0.1320
p Value Comment
Stratified analysis
param Type
Hazard Ratio (HR)
param Value
0.78
statistical Method
Log Rank

Complete source fields

analyses

ci Lower Limit
0.56
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
1.08
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY
p Value
0.1320
p Value Comment
Stratified analysis
param Type
Hazard Ratio (HR)
param Value
0.78
statistical Method
Log Rank

classes

categories
measurements
comment
Value is NA due to an insufficient number of participants with the event.
group Id
OG000
lower Limit
62.3
upper Limit
NA
value
81.1
group Id
OG001
lower Limit
34.6
upper Limit
75.6
value
54.2

denoms

counts
group Id
OG000
value
152
group Id
OG001
value
151
units
Participants

description

Overall survival (OS) was defined as the time from randomization to death from any cause.

dispersion Type

95% Confidence Interval

groups

description
Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
id
OG000
title
Alectinib
description
Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
id
OG001
title
Crizotinib

param Type

MEDIAN

population Description

ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.

reporting Status

POSTED

time Frame

From randomization until death (up to 10.5 years)

title

Overall Survival (OS)

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice